Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$19.12 +2.1%	$19.56	$16.50 ▼ $24.02	$1.66B	N/A	78,234 shs	10,980 shs
ARWR Arrowhead Pharmaceuticals	$12.08 +7.5%	$15.12	$9.57 ▼ $30.41	$1.66B	0.99	1.43 million shs	2.52 million shs
HRMY Harmony Biosciences	$28.50 +0.1%	$32.74	$26.47 ▼ $41.61	$1.63B	0.8	572,574 shs	638,634 shs
SIGA SIGA Technologies	$5.97 -0.3%	$5.75	$4.95 ▼ $12.83	$426.48M	1.03	773,323 shs	430,212 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	+2.14%	-6.69%	+2.25%	+1,911,999,900.00%	+1,911,999,900.00%
ARWR Arrowhead Pharmaceuticals	+7.47%	-2.11%	-18.38%	-38.87%	-45.90%
HRMY Harmony Biosciences	+0.14%	-3.49%	-19.22%	-29.56%	-3.06%
SIGA SIGA Technologies	-0.33%	-2.93%	+6.42%	-5.54%	-28.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	3.4173 of 5 stars	3.3	1.0	0.0	3.4	3.4	2.5	0.0
HRMY Harmony Biosciences	4.5265 of 5 stars	3.5	3.0	0.0	0.0	3.1	4.2	4.4
SIGA SIGA Technologies	1.9951 of 5 stars	0.0	1.0	0.0	0.0	3.9	0.8	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ARWR Arrowhead Pharmaceuticals	2.60	Moderate Buy	$41.44	243.08% Upside
HRMY Harmony Biosciences	3.00	Buy	$53.33	87.13% Upside
SIGA SIGA Technologies	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SIGA, AAPG, ARWR, and HRMY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
4/8/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
3/27/2025	AAPG Ascentage Pharma Group International	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight
3/18/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $44.00
2/27/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
2/25/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
2/20/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $42.00
2/19/2025	HRMY Harmony Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
2/19/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $50.00
2/14/2025	ARWR Arrowhead Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$51.00 ➝ $38.00
2/12/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00

(Data available from 4/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$980.65M	1.70	N/A	N/A	N/A	∞
ARWR Arrowhead Pharmaceuticals	$2.50M	663.52	N/A	N/A	$1.54 per share	7.84
HRMY Harmony Biosciences	$714.73M	2.29	$2.13 per share	13.38	$7.97 per share	3.58
SIGA SIGA Technologies	$138.72M	3.07	$0.94 per share	6.34	$2.77 per share	2.16

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$5.17	N/A	N/A	N/A	N/A	-236.60%	-64.09%	5/8/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.51	13.51	9.16	0.47	17.98%	23.16%	14.24%	4/29/2025 (Estimated)
SIGA SIGA Technologies	$68.07M	$0.82	4.98	4.78	N/A	49.33%	49.06%	38.72%	5/6/2025 (Estimated)

Latest SIGA, AAPG, ARWR, and HRMY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	N/A	N/A	N/A	$116.27 million	N/A
4/29/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	N/A	N/A	N/A	$184.26 million	N/A
3/11/2025	Q4 2024	SIGA SIGA Technologies	N/A	$0.63	N/A	$0.63	N/A	$81.40 million
2/25/2025	Q4 2024	HRMY Harmony Biosciences	$0.74	$0.85	+$0.11	$0.85	$201.25 million	$201.30 million
2/10/2025	Q1 2025	ARWR Arrowhead Pharmaceuticals	-$0.42	-$1.39	-$0.97	-$1.39	$19.05 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
SIGA SIGA Technologies	N/A	N/A	N/A	N/A	N/A

Latest SIGA, AAPG, ARWR, and HRMY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/8/2025	SIGA SIGA Technologies	special	$0.60		4/29/2025	4/29/2025	5/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	N/A	N/A	N/A
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
HRMY Harmony Biosciences	0.28	3.24	3.20
SIGA SIGA Technologies	N/A	8.10	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ARWR Arrowhead Pharmaceuticals	62.61%
HRMY Harmony Biosciences	86.23%
SIGA SIGA Technologies	55.40%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ARWR Arrowhead Pharmaceuticals	4.30%
HRMY Harmony Biosciences	23.60%
SIGA SIGA Technologies	1.54%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	87.07 million	N/A	N/A
ARWR Arrowhead Pharmaceuticals	400	137.32 million	120.68 million	Optionable
HRMY Harmony Biosciences	200	57.35 million	39.47 million	Optionable
SIGA SIGA Technologies	40	71.44 million	70.31 million	Optionable

SIGA, AAPG, ARWR, and HRMY Headlines

Recent News About These Companies

SIGA Technologies Target of Unusually High Options Trading (NASDAQ:SIGA)

April 19 at 3:39 AM | marketbeat.com

Siga Technologies Inc. (SIGA) Stock Moves -1.82%: What You Should Know

April 17, 2025 | msn.com

LSV Asset Management Has $974,000 Stock Holdings in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 17, 2025 | marketbeat.com

3 Stocks Upping Dividends & 1 With A 10% Special Dividend Yield (SIGA)

April 16, 2025 | dividendstocks.com

Siga Technologies Inc. (SIGA) Falls More Steeply Than Broader Market: What Investors Need to Know

April 15, 2025 | zacks.com

ExodusPoint Capital Management LP Makes New Investment in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 15, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Position Cut by Arrowstreet Capital Limited Partnership

April 12, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Announces $0.60 Special Dividend

April 10, 2025 | marketbeat.com

Siga Technologies Shares Climb on Special Dividend

April 8, 2025 | marketwatch.com

SIGA Declares Special Cash Dividend of $0.60 Per Share

April 8, 2025 | globenewswire.com

Prudential Financial Inc. Has $1.14 Million Stock Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 8, 2025 | marketbeat.com

Siga Technologies Inc. (SIGA) Declines More Than Market: Some Information for Investors

April 7, 2025 | zacks.com

SIGA Technologies: Asymmetric Upside, If 2025 Goes Right

April 7, 2025 | seekingalpha.com

KLP Kapitalforvaltning AS Purchases New Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

April 5, 2025 | marketbeat.com

American Century Companies Inc. Buys 114,270 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

April 5, 2025 | marketbeat.com

SIGA Technologies Sees Unusually High Options Volume (NASDAQ:SIGA)

April 4, 2025 | marketbeat.com

SIGA Technologies, Inc. (NASDAQ:SIGA) Holdings Lessened by First Wilshire Securities Management Inc.

April 3, 2025 | marketbeat.com

AltraVue Capital LLC Buys 326,630 Shares of SIGA Technologies, Inc. (NASDAQ:SIGA)

April 2, 2025 | marketbeat.com

Brokers Offer Predictions for SIGA FY2025 Earnings

March 31, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Cuts Position in SIGA Technologies, Inc. (NASDAQ:SIGA)

March 28, 2025 | marketbeat.com

Bank of New York Mellon Corp Has $1.74 Million Stake in SIGA Technologies, Inc. (NASDAQ:SIGA)

March 23, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SIGA, AAPG, ARWR, and HRMY Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$19.12 +0.40 (+2.14%)

As of 04/21/2025 04:00 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Arrowhead Pharmaceuticals NASDAQ:ARWR

$12.08 +0.84 (+7.47%)

Closing price 04/21/2025 04:00 PM Eastern

Extended Trading

$12.15 +0.07 (+0.58%)

As of 04:16 AM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Harmony Biosciences NASDAQ:HRMY

$28.50 +0.04 (+0.14%)

Closing price 04/21/2025 04:00 PM Eastern

Extended Trading

$26.84 -1.66 (-5.81%)

As of 04:35 AM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

SIGA Technologies NASDAQ:SIGA

$5.97 -0.02 (-0.33%)

Closing price 04/21/2025 04:00 PM Eastern

Extended Trading

$6.04 +0.08 (+1.26%)

As of 04:38 AM Eastern

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time